Show simple item record

dc.contributor.authorRuiz García, Yara
dc.contributor.authorSohn, Woo-Yun
dc.contributor.authorSeib, Kate L
dc.contributor.authorTaha, Muhamed-Kheir
dc.contributor.authorVázquez, Julio A
dc.contributor.authorde Lemos, Ana Paula S
dc.contributor.authorVadivelu, Kumaran
dc.contributor.authorPizza, Mariagrazia
dc.contributor.authorRappuoli, Rino
dc.contributor.authorBekkat-Berkani, Rafik
dc.date.accessioned2021-11-04T06:23:25Z
dc.date.available2021-11-04T06:23:25Z
dc.date.issued2021
dc.identifier.issn2059-0105
dc.identifier.doi10.1038/s41541-021-00388-3
dc.identifier.urihttp://hdl.handle.net/10072/409797
dc.description.abstractInfections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80-90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofpagefrom130
dc.relation.ispartofissue1
dc.relation.ispartofjournalNPJ Vaccines
dc.relation.ispartofvolume6
dc.subject.fieldofresearchBacteriology
dc.subject.fieldofresearchVirology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode310701
dc.subject.fieldofresearchcode310706
dc.subject.fieldofresearchcode3202
dc.titleLooking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationRuiz García, Y; Sohn, W-Y; Seib, KL; Taha, M-K; Vázquez, JA; de Lemos, APS; Vadivelu, K; Pizza, M; Rappuoli, R; Bekkat-Berkani, R, Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect., NPJ Vaccines, 2021, 6 (1), pp. 130
dcterms.dateAccepted2021-10-01
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2021-11-04T02:01:08Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorSeib, Kate


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record